Q-omics provides the consensus-scored ISM2 profile across patient tissues and cancer cell-line models. ISM2 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, ISM2 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, ISM2 RNA expression shows 15,211 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and KIRC as cancer lineages where ISM2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ISM2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ISM2 survival associations across molecular data types. ISM2 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (5) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ISM2 RNA expression–survival associations across cancer types. High ISM2 expression shows unfavorable associations in ACC, UVM, UCS, LIHC and LGG, but favorable associations in LUSC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for ISM2 RNA expression.
This table summarizes ISM2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for ISM2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ISM2 shows lower tumor expression in KIRC and UCEC and higher tumor expression in COAD, LUAD, LUSC and HNSC. The KIRC box plot shows higher ISM2 RNA expression in normal versus tumor tissue (log2 FC = −1.141, t-test p < 0.001).
This table shows molecular features associated with ISM2 in patient tissues and cancer cell lines. In patient samples, ISM2 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ISM2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BONE.
